Table 1.

Immunotherapeutic agents approved by FDA and EMA.

Tumor typeICIOther immunotherapies
Basal cell carcinomaPD1Anti-TLR7
Bladder cancerPD1, PD-L1BCG
Cervical cancerPD1None
Colorectal cancerPD1, PD1+CTLA-4None
Cutaneous squamous cell carcinomaPD1Anti-TLR3
Gastroesophageal cancerPD1None
Hepatocellular carcinomaPD1None
Head and neck cancerPD1, PD1+CHTNone
MelanomaPD1, CTLA-4, PD1+CTLA-4IL2, IFNα-2b, T-VEC
Merkel cell carcinomaPD1, PD-L1None
MSI-H or dMMR cancerPD1None
Non–small cell lung cancerPD1, PD-L1, PD1+CHT, PD-L1+CHT+anti-VEGFNone
Renal cell carcinomaPD1, PD1+CTLA-4, PD1/-L1+anti-VEGFRIL2
Small cell lung cancerPD1, PD-L1+CHTNone
Triple-negative breast cancerPD-L1+CHTNone
  • Abbreviations: BCG, Bacillus Calmette-Guérin; CHT, chemotherapy; CTLA-4, cytotoxic T lymphocyte antigen-4; dMMR, mismatch repair-deficient; EMA, European Medicines Agency; MSI-H, microsatellite instability-high; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; TLR, Toll-like receptor; T-VEC, Talimogene laherparepvec.